BioSpace News Archive

On Target Laboratories announced that the first patient was treated in its Phase III trial of OTL38 in detecting ovarian cancer. Linked with a near-infrared dye, OTL38 allows surgeons to visually identify cancer cells that can guide them in removing the cancer tissue.

Ferring Pharmaceuticals is buying Rebiotix. As part of the deal, will acquire Rebiotix’s lead program, RBX2660, a non-antibiotic treatment to prevent recurring Clostridium difficile infection (CDI).

Securing a promotion is a goal that many life science professionals have to progress their career. Whether it’s becoming a laboratory manager or lead scientist, getting promoted within your organization is a way to show your value.

Shares of Conatus Pharmaceuticals dropped 34.3 percent postmarket yesterday after the San Diego-based company announced mixed top-line results for its proof-of-concept trial in liver transplant patients with fibrosis or cirrhosis.

As legal battles over opioid drugs slowly move through the courts the U.S. Department of Justice is adding its weight to the matter. This week the DOJ asked the courts for permission to help settle disputes brought by state and local governments against opioid manufacturers and distributors.

After winning Amgen’s coveted 2017 Golden Ticket in December 2017 startup company QurAlis officially launched with financial backing from Amgen Ventures with a mission to develop a cure for Amyotrophic Lateral Sclerosis (ALS).

Boehringer Ingelheim and OSE Immunotherapeutics signed a collaboration and license deal to jointly develop OSE-172 for myeloid cancers.

U.S. sales of AbbVie’s blockbuster Humira is safe from a biosimilar challenge from Samsung Bioepis, a joint project between Samsung and Biogen, until 2023.

Eidos Therapeutics closed on a $64 million Series B financing round. The funds will be used to advance the company’s product candidate, AG10, into Phase II clinical trials and Phase III trials.

SignalRx Pharmaceuticals Inc., a clinical-stage company developing novel small-molecules therapeutics via in-silico design to simultaneously inhibit multiple key orthogonal and synergistic oncotargets for the treatment of cancer, today announced the presentation of its novel triple CDK4-6/PI3K/BRD4 inhibitor program and first-in-class triple inhibitor SRX3177.